Starlink satellites, several planets visible in Erie sky this week
If you saw a long trail of lights in the sky Tuesday night, you were not alone.
Starlink satellites were visible in Erie thanks to clear skies — That's according to PennWest planetarium director David Hurd.
Hurd said on any given night there are over 9,000 satellites orbiting the Earth.
If you missed them Tuesday night, Hurd said the Starlink satellites will be visible again Wednesday evening just after 6:30 p.m. and Thursday morning around 5:30 a.m.
See a line of lights in the sky tonight? Here's what they were
What makes them unique is their formation.
'They are in a train one after another after another and that's for high-speed internet Elon Musk and his SpaceX program so that's what people were seeing last night and they'll probably see again if it's clear tonight,' said Hurd.
Hurd said the satellites are nothing to be afraid of since they are at an altitude way above any commercial airliners.
Also of note — if you look up Wednesday, Mars, Jupiter and Venus are also expected to be visible.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
June 13-19, 2025 Sky Watch: Mars Meets Regulus, Saturn & Moon, Venus Shines
I was just thinking about Ray Bradbury - how he had this extraordinary gift for blending the fantastical with the deeply human. (Side note: If you're somehow unfamiliar with Bradbury, he's basically the literary giant who made science fiction respectable. You know Fahrenheit 451? The Martian Chronicles? That's our guy. He brought rocket ships and time machines into the realm of "serious literature" while the literary elite weren't looking, and by the time they noticed, it was too late - everyone was already in love with his work.) "We are an impossibility in an impossible universe," he once wrote. And doesn't that just hit you right in the existential sweet spot? Here we are, tiny specks on a spinning rock, somehow conscious enough to look up and wonder about it all. As we dive into this week's skywatching events, I keep coming back to this feeling - this profound appreciation for the mystery, the beauty, and yes, the privilege of witnessing the cosmos unfold above us. Whether you see it as divine creation or a marvel of nature, there's something utterly humbling about staring into the vast unknown. Stars are waiting - let's roll! There's something downright majestic about a nearly full moon hanging in the evening sky. At 97% illumination, our lunar neighbor is serving serious celestial drama on the 13th. While not technically full, this waning gibbous phase reveals crater details and highland regions that are often washed out during the full phase. Why should you care? Because this is the moon showing off its best features! Think of it as the lunar equivalent of perfect golden-hour lighting - all those crater shadows create a stunning three-dimensional effect. Time: Just after sunset until early morning Direction: Rising in the eastern sky Pro Tip: Those shadows along the terminator (the line between light and dark) make for absolutely stunning viewing through even modest binoculars. If you've never done a serious moon-gaze, now's your moment. Speaking of June 13th, here's a little cosmic perspective for you: On this day in 1983, Pioneer 10 quietly crossed Neptune's orbit, becoming the first human-made object to venture so far. Talk about a cosmic milestone! Launched back in 1972 with a modest 21-month mission plan, this overachiever kept communicating with Earth for over three decades - its last "hello" reaching us in 2003. Pioneer 10 is still traveling outward today, over 20.5 billion kilometers from Earth. It's just one of five spacecraft (along with Pioneer 11, Voyagers 1 & 2, and New Horizons) on trajectories that will eventually carry them into interstellar space. Our little mechanical emissaries to the stars, wandering eternally among them. Now this is celestial chemistry at its finest. Mars and Regulus, the brightest star in Leo, will perform an elegant cosmic dance just 0.8 degrees apart - that's less than the width of your pinky finger held at arm's length. Why should you care? It's a stunning color contrast - Mars with its distinctive rusty-copper glow and Regulus shining brilliant white-blue. The pair creates a visual treat that's both scientifically fascinating and aesthetically gorgeous. Time: After sunset for several hours Direction: Western sky in the Leo constellation If you're willing to sacrifice some sleep, you're in for a real celestial treat as the third-quarter Moon cozies up to ringed Saturn in the pre-dawn sky on the 19th. Their proximity in Aquarius creates one of those "wow" moments that makes even casual skywatchers reach for their phones to snap a picture. Time: Around 1:30 a.m. local time Direction: Eastern sky What you'll see: Third-quarter moon positioned near Saturn Pro Tip: A telescope will reveal Saturn's rings, which are currently tilted at an angle that offers a spectacular view. Set your alarm - this one's worth the early wake-up call. Venus is absolutely showing off right now as the "Morning Star," rising about two hours before the sun and outshining literally everything else in the pre-dawn sky. If you're an early riser (or haven't gone to bed yet - I don't judge), you simply can't miss it. Time: 2-3 hours before sunrise Direction: Eastern horizon Pro Tip: Venus is so bright that you can often spot it in twilight before other stars become visible. Use it as your anchor point to orient yourself to the morning sky. Leo is having quite the moment this week with the Mars-Regulus conjunction. This majestic constellation is one of the few that actually resembles what it's supposed to be—a lion, complete with the distinctive "sickle" forming the lion's mane and head. Finding Leo is easy: look for the backward question mark (the sickle) with Regulus as the dot at the bottom. The bright triangle of stars to the east forms the lion's hindquarters. And this week, with Mars visiting Regulus, you get an extra beacon guiding you right to it. While the planets and moon tend to steal the spotlight, this week also offers prime viewing for several magnificent deep-sky objects: The Milky Way Core: Late night observers get a special treat as our galaxy's center rises, revealing a dense band of stars, dust, and gas that creates one of the most breathtaking sights in astronomy. You'll need dark skies away from city lights, but it's absolutely worth the drive. M13 Hercules Globular Cluster: High overhead in the evening, this ancient ball of thousands of stars looks like a fuzzy cotton ball to the naked eye, but explodes into a dazzling sphere through even modest telescopes. Beehive Cluster (M44): This open star cluster in Cancer is visible after sunset and looks spectacular through binoculars. The universe is putting on quite the performance - all you need to do is look up. And remember, every time you gaze at these celestial wonders, you're participating in the same activity that has captivated humans for thousands of years. There's something profoundly connecting about that, don't you think? NASA Astronaut Shoots Breathtaking Aurora From Space Strawberry Moon Stunner: Full Moon Views Around The Globe Astronaut Marvels At Lightning From Space
Yahoo
3 hours ago
- Yahoo
Educators learn to use AI tools at Niswonger School Success Symposium
KINGSPORT, Tenn. (WJHL) – At this year's Niswonger Foundation School Success Symposium, teachers from around East Tennessee gathered to learn more about changing technology in the classroom, including the uses of AI. Niswonger Foundation CEO Steve Barnett said the topic of the symposium was chosen by the teachers attending. This year, Barnett said teachers decided to learn about how AI tools can be used in the classroom. 'It's emerging and it's going to continue to change over time,' Barnett said. 'And we want to make sure that it's something that teachers feel comfortable with because they see your students use it, teachers can use it and we want to make sure everybody has what they need to be able to be successful with our use of AI in the classroom.' 2024 National Teacher of the Year Missy Testerman spoke to over 600 teachers about how even though AI will change things, human connection with students will always be needed. Testerman said, for example, AI tools will not help students who may be nervous about a test. 'It is something that we're going to have to embrace because we want our students to be prepared for the future,' Testerman said. 'We just have to figure out a way to take in all the advantages that we can of ed tech while we maintain that spirit of humanity.' Live music, kids fishing day and more | Weekend events in the Tri-Cities Beth Zeisenis, also known as 'Beth Z, Your Nerdy Best Friend,' was this year's keynote speaker for the symposium. 'Teachers have such a tough time right now with the whole concept of AI and so what I tried to do was give them some tools that they can use right away, plus some bigger concepts about how it works and where it's going,' Zeisenis said. Zeisenis went through many AI programs including Chat GPT and Magic School Plus. She said teachers can use AI tools to complete small tasks such as making lesson plans. Zeisenis also said teachers need to have conversations with students about how to properly use AI instead of trying to stop students from using it altogether. 'We need to go into conversations with our students about trusting each other and about learning this together, because if we go in with a defensive posture, if we go in distrusting each other, then you have a challenge because it's there all the time,' Zeisenis SAID. 'It's going to be like calculators in our pockets. They're going to have it for the rest of their lives. So how can we teach students and each other how we can use that rather than being afraid of it or feeling like it's an affront to what's going on?' Zeisenis and Testerman both encourage East Tennessee teachers to talk to school administrators about the ways AI can be used in the classroom. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
